Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VM-1500 in healthy volunteers
NCT02489435Phase 1Completed
- Sponsor
- Viriom Inc
- Start
- Jul 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of depulfavirine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Viriom Inc. Primary endpoints: Safety and tolerability of VM-1500 at 4 weeks, Peak Plasma concentration of VM-1500 at 4 weeks and 2 more. Started Jul 2012; status: completed.
02
Drugs
depulfavirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02489435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489435.